SHR-1314

Phase 1UNKNOWN

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Moderate-to-severe Plaque Psoriasis

Conditions

Moderate-to-severe Plaque Psoriasis

Trial Timeline

Aug 2, 2018 → Jul 30, 2019

NCT ID

NCT03710681

About SHR-1314

SHR-1314 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Moderate-to-severe Plaque Psoriasis. The current trial status is unknown. This product is registered under clinical trial identifier NCT03710681. Target conditions include Moderate-to-severe Plaque Psoriasis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04527484	Phase 1	UNKNOWN	Aug 20, 2020	Mar 30, 2021	Bioequivalence
NCT04326881	Phase 1	UNKNOWN	Apr 7, 2020	Nov 30, 2020	Pharmacokinetic
NCT03710681	Phase 1	UNKNOWN	Aug 2, 2018	Jul 30, 2019	Moderate-to-severe Plaque Psoriasis
NCT03704428	Phase 1	Completed	Apr 19, 2018	Jan 14, 2020	Axial Spondyloarthritis

Competing Products

13 competing products in Moderate-to-severe Plaque Psoriasis

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	80
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo	Sun Pharmaceutical	Phase 2/3	65
SHR-1314 + Placebo	Jiangsu Hengrui Medicine	Phase 1/2	41
SHR-1314 + Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Indacaterol + Control	Novartis	Phase 3	77
Deucravacitinib	Bristol Myers Squibb	Pre-clinical	22
Dupilumab + Placebo	Sanofi	Phase 3	76
dupilumab	Sanofi	Approved	84
dupilumab	Sanofi	Pre-clinical	22
Ponesimod	Vanda Pharmaceuticals	Phase 3	69
sufentanil sublingual tablet 30 mcg	Talphera	Phase 3	69
Zalviso™ 15 mcg	Talphera	Phase 3	69
sufentanil sublingual 30 mcg tablet	Talphera	Phase 3	69

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved